{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T10:33:55Z","timestamp":1791023635897,"version":"4.1.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bone"],"published-print":{"date-parts":[[2007,2]]},"DOI":"10.1016\/j.bone.2006.08.002","type":"journal-article","created":{"date-parts":[[2006,9,23]],"date-time":"2006-09-23T11:29:43Z","timestamp":1159010983000},"page":"265-273","source":"Crossref","is-referenced-by-count":30,"title":["Effects of ibandronate on bone quality: Preclinical studies"],"prefix":"10.1016","volume":"40","author":[{"given":"F.","family":"Bauss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.W.","family":"Dempster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2006.08.002_bib1","unstructured":"Committee for Proprietary Medicinal Products (CPMP). Note for guidance on involutional osteoporosis in women. London, European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit 2001."},{"key":"10.1016\/j.bone.2006.08.002_bib2","first-page":"1166","article-title":"A comparison of single and multi-site BMC measurements for assessment of spine fracture probability","volume":"30","author":"Wasnich","year":"1989","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bone.2006.08.002_bib3","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1359\/jbmr.2001.16.12.2163","article-title":"Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture","volume":"16","author":"Chesnut","year":"2001","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2006.08.002_bib4","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0002-9343(01)01124-X","article-title":"Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs","volume":"112","author":"Cummings","year":"2002","journal-title":"Am. J. Med."},{"issue":"Suppl. 3","key":"10.1016\/j.bone.2006.08.002_bib5","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1007\/s00198-002-1345-4","article-title":"Bone strength and its determinants","volume":"14","author":"Ammann","year":"2003","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2006.08.002_bib6","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1359\/JBMR.050211","article-title":"Revival of bone strength; the bottom line","volume":"20","author":"J\u00e4rvinen","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2006.08.002_bib7","first-page":"1","article-title":"Osteoporosis prevention, diagnosis, and therapy","volume":"17","author":"National Institutes of Health","year":"2000","journal-title":"NIH Consens. Statement"},{"key":"10.1016\/j.bone.2006.08.002_bib8","series-title":"Guidelines for preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis","author":"United States Food and Drug Administration (FDA)","year":"1994"},{"key":"10.1016\/j.bone.2006.08.002_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clinthera.2004.12.020","article-title":"The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management","volume":"27","author":"Felsenberg","year":"2005","journal-title":"Clin. Ther."},{"key":"10.1016\/j.bone.2006.08.002_bib10","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1359\/JBMR.041114","article-title":"Perspective. Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling","volume":"20","author":"Riggs","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2006.08.002_bib11","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/BF00334542","article-title":"The \u2018bone quality\u2019 problem","volume":"51","author":"Wallach","year":"1992","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2006.08.002_bib12","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/8756-3282(93)90081-K","article-title":"Basic biomechanical measurements of bone: a tutorial","volume":"14","author":"Turner","year":"1993","journal-title":"Bone"},{"issue":"Suppl. 2","key":"10.1016\/j.bone.2006.08.002_bib13","first-page":"S13","article-title":"Mechanisms of osteoporosis therapy: a bone strength perspective","author":"Bouxsein","year":"2002","journal-title":"Clin. Cornerstone"},{"key":"10.1016\/j.bone.2006.08.002_bib14","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00198-003-1530-0","article-title":"Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study","volume":"15","author":"Recker","year":"2004","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2006.08.002_bib15","series-title":"Guidelines for preclinical evaluation and clinical trials in osteoporosis","author":"World Health Organization","year":"1998"},{"key":"10.1016\/j.bone.2006.08.002_bib16","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s001980050161","article-title":"Importance of preclinical studies in the development of drugs for treatment of osteoporosis: a review related to the 1998 WHO guidelines","volume":"9","author":"Bonjour","year":"1999","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2006.08.002_bib17","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0169-6009(91)90124-I","article-title":"The ovariectomized rat model of postmenopausal bone loss","volume":"15","author":"Kalu","year":"1999","journal-title":"Bone Miner."},{"key":"10.1016\/j.bone.2006.08.002_bib18","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0169-6009(92)90809-R","article-title":"On the rat model of human osteoporosis","volume":"18","author":"Frost","year":"1992","journal-title":"Bone Miner."},{"key":"10.1016\/j.bone.2006.08.002_bib19","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/bjc.1997.48","article-title":"Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia","volume":"75","author":"Ralston","year":"1997","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bone.2006.08.002_bib20","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1159\/000026952","article-title":"The new bisphosphonate ibandronate in the treatment of tumor-induced hypercalcemia","volume":"22","author":"Herrmann","year":"1999","journal-title":"Onkologie"},{"issue":"Suppl. 11","key":"10.1016\/j.bone.2006.08.002_bib21","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0093-7754(01)90232-5","article-title":"Dosing regimens and main adverse events of bisphosphonates","volume":"28","author":"Body","year":"2001","journal-title":"Semin. Oncol."},{"issue":"Suppl. 5","key":"10.1016\/j.bone.2006.08.002_bib22","first-page":"168","article-title":"Oral daily ibandronate: an effective and convenient therapy for the reduction of skeletal complications in breast cancer patients with bone metastases (Bondronat MF4434 Study Group)","volume":"13","author":"Tripathy","year":"2002","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bone.2006.08.002_bib23","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/annonc\/mdg367","article-title":"Ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases (MF4265 study group)","volume":"14","author":"Body","year":"2003","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bone.2006.08.002_bib24","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1517\/14656566.5.11.2341","article-title":"Efficacy and safety of ibandronate in the treatment of neoplastic bone disease","volume":"5","author":"Pecherstorfer","year":"2004","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.bone.2006.08.002_bib25","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1358\/dot.2003.39.11.799465","article-title":"Ibandronate: new option in the treatment of osteoporosis","volume":"39","author":"Adami","year":"2003","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.bone.2006.08.002_bib26","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.1742-1241.2003.tb10518.x","article-title":"Ibandronate: a potent new bisphosphonate in the management of postmenopausal osteoporosis","volume":"57","author":"Papapoulos","year":"2003","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.bone.2006.08.002_bib27","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00198-003-1425-0","article-title":"Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study","volume":"14","author":"Ringe","year":"2003","journal-title":"Osteoporos. Int."},{"issue":"Suppl. 5","key":"10.1016\/j.bone.2006.08.002_bib28","doi-asserted-by":"crossref","first-page":"87S","DOI":"10.1016\/S8756-3282(99)00072-1","article-title":"Ibandronate treatment in Paget's disease of bone","volume":"24","author":"Grauer","year":"1999","journal-title":"Bone"},{"key":"10.1016\/j.bone.2006.08.002_bib29","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/clinchem\/46.5.684","article-title":"Short- and long-term effects of ibandronate treatment on bone turnover in Paget disease of bone","volume":"46","author":"Woitge","year":"2000","journal-title":"Clin. Chem."},{"key":"10.1016\/j.bone.2006.08.002_bib30","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2006.08.002_bib31","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.bone.2004.01.007","article-title":"Efficacy and safety of ibandronate given by intravenous injection once every 3\u00a0months","volume":"34","author":"Adami","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.bone.2006.08.002_bib32","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.bone.2004.01.008","article-title":"Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis","volume":"34","author":"Recker","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.bone.2006.08.002_bib33","first-page":"4095","article-title":"Intermittent intravenous ibandronate injection regimens provide at least equivalent efficacy to daily oral ibandronate: 1-year results from DIVA","volume":"50","author":"Recker","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bone.2006.08.002_bib34","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1359\/JBMR.050313","article-title":"Monthly oral ibandronate therapy in postmenopausal osteoporosis: one-year results from the MOBILE study","volume":"20","author":"Miller","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2006.08.002_bib35","first-page":"2200","article-title":"Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats","volume":"29","author":"Bauss","year":"2002","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.bone.2006.08.002_bib36","first-page":"990","article-title":"Total administered dose of ibandronate determines its effects on bone mass and architecture in ovariectomized aged rats","volume":"29","author":"Bauss","year":"2002","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.bone.2006.08.002_bib37","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1002\/jbmr.5650081109","article-title":"A new bisphosphonate, BM 21.0955, prevents bone loss associated with cessation of ovarian function in experimental dogs","volume":"8","author":"Monier-Faugere","year":"1993","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2006.08.002_bib38","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1359\/jbmr.1999.14.10.1768","article-title":"Intermittent and continuous administration of the bisphosphonate ibandronate in ovariohysterectomized beagle dogs: effects on bone morphometry and mineral properties","volume":"14","author":"Monier-Faugere","year":"1999","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2006.08.002_bib39","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S8756-3282(02)00923-7","article-title":"Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys","volume":"32","author":"Smith","year":"2003","journal-title":"Bone"},{"key":"10.1016\/j.bone.2006.08.002_bib40","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1359\/JBMR.040809","article-title":"Intermittent ibandronate preserves bone quality and bone strength in the lumbar spine after 16\u00a0months of treatment in the ovariectomized cynomolgus monkey","volume":"19","author":"M\u00fcller","year":"2004","journal-title":"J. Bone Miner. Res."},{"issue":"Suppl. 1","key":"10.1016\/j.bone.2006.08.002_bib41","first-page":"S371","article-title":"The minipig is a good model for glucocorticoid-induced bone loss and shows efficacy of ibandronate treatments for this disorder","volume":"17","author":"Glueer","year":"2002","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2006.08.002_bib42","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00198-004-1612-7","article-title":"Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing","volume":"15","author":"Bauss","year":"2004","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2006.08.002_bib43","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/jbmr.5650060915","article-title":"BM 21.0955, a potent new bisphosphonate to inhibit bone resorption","volume":"6","author":"M\u00fchlbauer","year":"1991","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2006.08.002_bib44","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/BF02672503","article-title":"Lifelong administration of high doses of ibandronate increases bone mass and maintains bone quality of lumbar vertebrae in rats","volume":"8","author":"Lalla","year":"1998","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2006.08.002_bib45","first-page":"0418","article-title":"Effects of ibandronate on mechanical bone strength in glucocorticoid-induced bone loss in a minipig model","volume":"28","author":"Helfenstein","year":"2003","journal-title":"Transactions of the 49th Annual Meeting of the Orthopaedic Research Society"},{"key":"10.1016\/j.bone.2006.08.002_bib46","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1302\/0301-620X.82B1.9483","article-title":"Treatment with ibandronate preserves bone in experimental tumour-induced bone loss","volume":"82","author":"Kurth","year":"2000","journal-title":"J. Bone Jt. Surg., Br."},{"key":"10.1016\/j.bone.2006.08.002_bib47","first-page":"P13","article-title":"Disuse bone loss in hindquarter suspended rats: partial weightbearing, exercise and ibandronate treatment as countermeasures","volume":"7","author":"Schultheis","year":"2000","journal-title":"J. Gravit. Physiol."},{"key":"10.1016\/j.bone.2006.08.002_bib48","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/BF01320915","article-title":"Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical properties","volume":"53","author":"Guy","year":"1993","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2006.08.002_bib49","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/jbmr.5650071207","article-title":"Effects of 4-amino-1-hydroxybutylidene bisphosphonate on bone biomechanics in rats","volume":"7","author":"Toolan","year":"1992","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2006.08.002_bib50","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/jbmr.5650100613","article-title":"Intermittent cyclical etidronate treatment maintains the mass, structure and the mechanical property of bone in ovariectomized rats","volume":"10","author":"Katsumata","year":"1995","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2006.08.002_bib51","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S8756-3282(98)00110-0","article-title":"Effect of clodronate treatment on established bone loss in overiectomized rats","volume":"23","author":"Kippo","year":"1998","journal-title":"Bone"},{"key":"10.1016\/j.bone.2006.08.002_bib52","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00198-004-1588-3","article-title":"Loss of vertebral bone and mechanical in estrogen-deficient rats is prevented by long-term administration of zoledronic acid","volume":"15","author":"Glatt","year":"2004","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2006.08.002_bib53","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1172\/JCI116872","article-title":"The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates","volume":"92","author":"Balena","year":"1993","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bone.2006.08.002_bib54","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1359\/jbmr.2002.17.7.1139","article-title":"Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three-dimensional microcomputed tomography","volume":"17","author":"Borah","year":"2002","journal-title":"J. Bone Miner. Res."},{"issue":"Suppl. 5","key":"10.1016\/j.bone.2006.08.002_bib55","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s00198-003-1474-4","article-title":"Bone microarchitecture and strength","volume":"14","author":"Dempster","year":"2003","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2006.08.002_bib56","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/8756-3282(96)87969-5","article-title":"Mechanical properties of cancellous and cortical bone after long term ibandronate dosing in beagle dogs","volume":"17","author":"Affentranger","year":"1995","journal-title":"Bone"},{"key":"10.1016\/j.bone.2006.08.002_bib57","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.vascn.2003.11.003","article-title":"New model for simulation of fracture repair in full-grown beagle dogs: model characterization and results from a long-term study with ibandronate","volume":"50","author":"Bauss","year":"2004","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.bone.2006.08.002_bib58","first-page":"40","article-title":"Ibandronate reduced the time of implant osseointegration in a rat model","volume":"30","author":"Eberhardt","year":"2002","journal-title":"Bone"},{"key":"10.1016\/j.bone.2006.08.002_bib59","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1055\/s-2005-836752","article-title":"Improved osseointegration and periprosthetic bone volume around cementless metal implants under bisphosphonate treatment (article in German)","volume":"143","author":"Eberhardt","year":"2005","journal-title":"Z. Orthop. Ihre Grenzgeb."},{"key":"10.1016\/j.bone.2006.08.002_bib60","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1007\/s00776-005-0955-z","article-title":"High dose treatment of nitrogen-containing bisphosphonate ibandronate is required for osseointegration of cementless metal implants","volume":"10","author":"Eberhardt","year":"2005","journal-title":"J. Orthop. Sci."},{"key":"10.1016\/j.bone.2006.08.002_bib61","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/01.blo.0000201170.57141.66","article-title":"Osseointegration of cementless implants with different bisphosphonate regimens","volume":"447","author":"Eberhardt","year":"2006","journal-title":"Clin. Orthop. Relat. Res"},{"key":"10.1016\/j.bone.2006.08.002_bib62","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.bone.2004.12.017","article-title":"The bisphosphonate ibandronate improves implant integration in osteopenic ovariectomized rats","volume":"37","author":"Kurth","year":"2005","journal-title":"Bone"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328206006417?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328206006417?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T23:21:50Z","timestamp":1683588110000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328206006417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2]]},"references-count":62,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,2]]}},"alternative-id":["S8756328206006417"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2006.08.002","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2007,2]]}}}